Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Risk of Pneumococcal Disease in Children With Chronic Medical Conditions in the Era of Pneumococcal Conjugate Vaccine.

Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J.

Clin Infect Dis. 2014 May 13. pii: ciu348. [Epub ahead of print]

PMID:
24825867
[PubMed - as supplied by publisher]
2.

Letter to the editor.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Jul;35(7):1048-50. doi: 10.1016/j.clinthera.2013.05.010. Epub 2013 Jun 24. No abstract available.

PMID:
23806326
[PubMed - indexed for MEDLINE]
3.

Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States.

McGarry LJ, Gilmore KE, Rubin JL, Klugman KP, Strutton DR, Weinstein MC.

BMC Infect Dis. 2013 May 21;13:229. doi: 10.1186/1471-2334-13-229.

PMID:
23687999
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
[PubMed - indexed for MEDLINE]
5.

Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.

Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR.

Expert Rev Vaccines. 2012 Oct;11(10):1235-47. doi: 10.1586/erv.12.99. Epub 2012 Nov 21. Review.

PMID:
23170992
[PubMed - indexed for MEDLINE]
6.

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data.

Strutton DR, Farkouh RA, Rubin JL, McGarry LJ, Loiacono PM, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC.

BMC Infect Dis. 2012 Aug 3;12:175. doi: 10.1186/1471-2334-12-175.

PMID:
22863074
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.

Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, Klok R, Papanicolaou S.

J Infect. 2012 Jan;64(1):54-67. doi: 10.1016/j.jinf.2011.10.015. Epub 2011 Nov 4.

PMID:
22085813
[PubMed - indexed for MEDLINE]
8.

Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US.

Shea KM, Weycker D, Stevenson AE, Strutton DR, Pelton SI.

Vaccine. 2011 Oct 19;29(45):8042-8. doi: 10.1016/j.vaccine.2011.08.057. Epub 2011 Aug 24.

PMID:
21871518
[PubMed - indexed for MEDLINE]
9.

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.

Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC.

Vaccine. 2010 Nov 10;28(48):7634-43. doi: 10.1016/j.vaccine.2010.09.049. Epub 2010 Sep 28.

PMID:
20883739
[PubMed - indexed for MEDLINE]
10.

Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.

Rubin JL, McGarry LJ, Klugman KP, Strutton DR, Gilmore KE, Weinstein MC.

BMC Infect Dis. 2010 Jan 21;10:14. doi: 10.1186/1471-2334-10-14.

PMID:
20092638
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.

Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR.

Vaccine. 2009 Nov 5;27(47):6483-94. doi: 10.1016/j.vaccine.2009.08.045. Epub 2009 Aug 29.

PMID:
19720366
[PubMed - indexed for MEDLINE]
12.

Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations.

Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, Botteman MF.

Vaccine. 2009 Jul 23;27(34):4694-703. doi: 10.1016/j.vaccine.2009.05.062. Epub 2009 Jun 9.

PMID:
19520197
[PubMed - indexed for MEDLINE]
13.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
[PubMed - indexed for MEDLINE]
14.

Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia.

Strutton DR, Gutierrez B, Blanchette CM.

Am J Health Syst Pharm. 2008 Jan 1;65(1):42-8.

PMID:
18159038
[PubMed - indexed for MEDLINE]
15.

US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey.

Strutton DR, Kowalski JW, Glaser DA, Stang PE.

J Am Acad Dermatol. 2004 Aug;51(2):241-8.

PMID:
15280843
[PubMed - indexed for MEDLINE]
16.

Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies.

Strutton DR, Walt JG.

J Glaucoma. 2004 Jun;13(3):221-6.

PMID:
15118466
[PubMed - indexed for MEDLINE]
17.

Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: Economic-based decision-making.

Strutton DR, Stang PE.

J Pediatr. 2003 Nov;143(5 Suppl):S157-62.

PMID:
14615715
[PubMed - indexed for MEDLINE]
18.

Impact of smoking on respiratory illness-related outpatient visits among 50- to 75-year-olds in the United States.

Hoffman LH, Strutton DR, Stang PE, Hogue SL.

Clin Ther. 2002 Feb;24(2):317-24.

PMID:
11911561
[PubMed - indexed for MEDLINE]
19.

Estimated coronary heart disease attributable to insulin resistance in populations with and without type 2 diabetes mellitus.

Strutton DR, Stang PE, Erbey JR, Lydick E.

Am J Manag Care. 2001 Aug;7(8):765-73.

PMID:
11519236
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk